I85PREP
⌘ K
DABAT study materials
DABAT study resources

DABAT practice questions

One question at a time. Build your DABAT understanding.

First 50 of 200 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Scientific and Clinical Foundations of Toxicology

Which enzyme system is primarily responsible for phase I oxidative metabolism of xenobiotics in the liver?

  1. Glucuronosyltransferase system
  2. Sulfotransferase system
  3. Cytochrome P450 monooxygenase system Correct answer.
  4. Glutathione S-transferase system

Explanation

Phase I oxidation is dominated by the cytochrome P450 superfamily, membrane-bound heme proteins in the smooth endoplasmic reticulum that insert one oxygen atom into the substrate. The other listed enzymes are phase II conjugating enzymes that attach polar groups rather than performing oxidation.

Question 2Scientific and Clinical Foundations of Toxicology

Acetaminophen hepatotoxicity is classically attributed to the accumulation of which reactive metabolite?

  1. Acrolein
  2. Formaldehyde
  3. Phosgene
  4. N-acetyl-p-benzoquinone imine (NAPQI) Correct answer.

Explanation

At supratherapeutic doses, saturation of glucuronidation and sulfation shunts acetaminophen to CYP2E1-mediated oxidation, generating NAPQI. NAPQI depletes hepatic glutathione and binds cellular proteins, producing centrilobular necrosis.

Question 3Scientific and Clinical Foundations of Toxicology

A chemical that binds to a receptor at the same site as the endogenous ligand but produces no measurable response is best described as which type of agent?

  1. Full agonist
  2. Inverse agonist
  3. Competitive antagonist Correct answer.
  4. Partial agonist

Explanation

A competitive antagonist occupies the orthosteric site without activating the receptor, blocking agonist access in a surmountable manner. A partial agonist still produces some response, and an inverse agonist reduces constitutive activity below baseline.

Question 4Scientific and Clinical Foundations of Toxicology

The no-observed-adverse-effect level (NOAEL) is defined as which of the following?

  1. The dose producing a 50% reduction in body weight
  2. The highest dose tested that produces no statistically or biologically significant adverse effect Correct answer.
  3. The lowest dose at which any biological change is detected
  4. The dose at which 50% of animals die

Explanation

The NOAEL is the highest administered dose in a study at which no biologically significant increase in adverse effects is observed compared with controls. It is used as the starting point for deriving reference doses and acceptable daily intakes after applying uncertainty factors.

Question 5Scientific and Clinical Foundations of Toxicology

Which of the following is a correct statement about the relationship between dose and response in toxicology?

  1. Graded responses describe the proportion of a population affected, whereas quantal responses describe intensity in an individual
  2. Quantal responses cannot be used to derive a median effective dose
  3. Both graded and quantal responses describe only lethality
  4. Graded responses describe the intensity of effect in an individual, whereas quantal responses describe the proportion of a population affected Correct answer.

Explanation

A graded dose-response curve plots the magnitude of response in a single individual or system against dose. A quantal curve plots the fraction of a population responding at each dose and is used to derive the ED50 or LD50.

Question 6Scientific and Clinical Foundations of Toxicology

Which of the following best describes the role of glutathione in cellular defense against reactive electrophiles?

  1. It acts as a proton donor that neutralizes acids in the stomach
  2. It acts as a nucleophilic cofactor that conjugates electrophiles, facilitating their elimination Correct answer.
  3. It serves as an oxygen carrier in the bloodstream
  4. It acts as a calcium channel blocker in the plasma membrane

Explanation

Glutathione contains a cysteine thiol that acts as a nucleophile, reacting with electrophilic metabolites either spontaneously or via glutathione S-transferases. The resulting conjugates are more water-soluble and are exported or further metabolized for excretion.

Question 7Scientific and Clinical Foundations of Toxicology

Which organ is the principal site of first-pass metabolism for orally administered xenobiotics?

  1. Liver Correct answer.
  2. Lung
  3. Skin
  4. Kidney

Explanation

After absorption from the gastrointestinal tract, blood draining into the portal vein passes through the liver before reaching systemic circulation. Hepatic biotransformation during this passage constitutes first-pass metabolism.

Question 8Scientific and Clinical Foundations of Toxicology

Which of the following describes a threshold effect in toxicology?

  1. A response that occurs only after repeated exposure
  2. A response that occurs at any dose, however small
  3. A response that is independent of dose
  4. A dose below which no adverse response occurs, implying a safe level may exist Correct answer.

Explanation

Many toxic effects exhibit a threshold because homeostatic and detoxification mechanisms can handle low doses without adverse consequence. Below that dose, no effect is observed, which is the basis for setting reference values.

Question 9Scientific and Clinical Foundations of Toxicology

A patient presents with miosis, salivation, lacrimation, urination, diarrhea, and bronchoconstriction after pesticide exposure. Which mechanism best explains these findings?

  1. Blockade of nicotinic receptors at the neuromuscular junction
  2. Inhibition of monoamine oxidase, increasing catecholamine levels
  3. Blockade of muscarinic receptors at parasympathetic end organs
  4. Inhibition of acetylcholinesterase, causing acetylcholine accumulation at cholinergic synapses Correct answer.

Explanation

Organophosphate and carbamate insecticides inhibit acetylcholinesterase, so acetylcholine accumulates and overstimulates muscarinic and nicotinic receptors. The resulting cholinergic syndrome includes the classic SLUDGE features along with miosis and bronchorrhea.

Question 10Scientific and Clinical Foundations of Toxicology

An experimental drug shows high hepatic clearance that approaches liver blood flow. What is the expected effect of this property on oral bioavailability?

  1. Oral bioavailability will exceed intravenous bioavailability
  2. Oral bioavailability will be low because of extensive first-pass extraction Correct answer.
  3. Oral bioavailability will be unaffected because clearance is independent of route
  4. Oral bioavailability will be high because hepatic clearance is efficient

Explanation

When hepatic clearance approaches liver blood flow, the liver extracts nearly all drug presented to it, giving a high extraction ratio. For an oral dose, this extensive first-pass extraction reduces the fraction reaching systemic circulation, lowering bioavailability.

Question 11Scientific and Clinical Foundations of Toxicology

Which of the following best explains why chronic exposure to a toxicant may produce effects at doses that caused no acute toxicity?

  1. The threshold dose is always lower for acute than for chronic exposure
  2. Repeated exposure allows cumulative tissue burden and progressive loss of adaptive capacity Correct answer.
  3. Chronic exposure always increases metabolic activation to the same degree
  4. Repeated exposure decreases the toxicant's half-life in the body

Explanation

With repeated dosing, the body burden can accumulate when elimination is incomplete, and adaptive defenses such as glutathione stores may become depleted. These processes can allow injury to emerge at doses that were tolerated acutely.

Question 12Scientific and Clinical Foundations of Toxicology

A chemical is a known inducer of CYP3A4. Which consequence is most likely when it is co-administered with a drug metabolized by CYP3A4?

  1. Increased plasma concentration of the co-administered drug due to inhibited metabolism
  2. Decreased plasma concentration of the co-administered drug due to increased metabolism Correct answer.
  3. Increased renal excretion of unchanged co-administered drug
  4. No change in the co-administered drug because CYP3A4 is not inducible

Explanation

Enzyme induction increases the amount of CYP3A4 protein, raising the metabolic clearance of substrates. For a co-administered CYP3A4 substrate, this typically lowers its systemic exposure and may reduce efficacy.

Question 13Scientific and Clinical Foundations of Toxicology

Which of the following is the most appropriate interpretation of a positive result in the bacterial reverse mutation (Ames) assay?

  1. The test substance is definitely carcinogenic to humans
  2. The test substance is a developmental toxicant
  3. The test substance induced mutations in the bacterial strains under the assay conditions Correct answer.
  4. The test substance caused chromosomal breakage in vivo

Explanation

The Ames test detects reversions to prototrophy in engineered Salmonella strains, indicating that the substance can cause point mutations in bacteria. A positive result is a hazard signal that may warrant further testing, but it does not by itself prove human carcinogenicity.

Question 14Scientific and Clinical Foundations of Toxicology

In a two-year rodent bioassay, an increased incidence of liver tumors is observed only at a dose that also causes marked hepatotoxicity and reduced survival. What is the most appropriate interpretation?

  1. The result should be ignored because tumors occurred
  2. The tumor response may be secondary to chronic tissue injury and should be evaluated with caution Correct answer.
  3. The finding proves a threshold for all carcinogens
  4. The substance is conclusively a direct-acting carcinogen at all doses

Explanation

Tumors arising only at a dose with substantial organ toxicity and reduced survival can reflect regenerative proliferation and other secondary mechanisms rather than direct genotoxicity. Interpretation should consider dose-response, mechanistic data, and whether the maximum tolerated dose was exceeded.

Question 15Scientific and Clinical Foundations of Toxicology

Which of the following best describes the concept of toxicokinetics?

  1. The study of the adverse effects of chemicals on living organisms
  2. The study of how the body handles a toxicant over time, including absorption, distribution, metabolism, and excretion Correct answer.
  3. The study of the mechanism by which toxicants interact with receptors
  4. The study of population-level exposure to environmental chemicals

Explanation

Toxicokinetics quantifies the time course of a toxicant in the body through absorption, distribution, metabolism, and excretion. It is distinguished from toxicodynamics, which concerns the effects of the toxicant on the organism.

Question 16Scientific and Clinical Foundations of Toxicology

A worker is exposed to a volatile solvent in an enclosed space. Which exposure route is generally the most significant contributor to systemic dose in this scenario?

  1. Ingestion
  2. Injection
  3. Dermal absorption
  4. Inhalation Correct answer.

Explanation

Volatile solvents in enclosed spaces generate airborne concentrations that are readily inhaled, and the large alveolar surface area and pulmonary blood flow favor rapid uptake. Dermal and oral routes are usually secondary for volatile compounds in this setting.

Question 17Scientific and Clinical Foundations of Toxicology

Which of the following statements about the dose-response curve for essential trace elements such as selenium is correct?

  1. Both deficiency and excess can produce adverse effects, giving a U-shaped or hormetic relationship Correct answer.
  2. Deficiency effects are unrelated to dose
  3. Any intake above zero is toxic
  4. Toxicity decreases monotonically as intake increases

Explanation

Essential elements have a nutritional requirement range; intakes below it cause deficiency, and intakes above the tolerable upper level cause toxicity. This produces a U-shaped relationship between intake and adverse outcome.

Question 18Scientific and Clinical Foundations of Toxicology

Which of the following is the primary mechanism by which carbon monoxide produces tissue hypoxia?

  1. Blocking alveolar diffusion of oxygen by forming a physical barrier
  2. Forming methemoglobin by oxidizing ferrous iron to ferric iron
  3. Binding to hemoglobin with high affinity, reducing oxygen-carrying capacity and shifting the dissociation curve Correct answer.
  4. Inhibiting cytochrome c oxidase in the electron transport chain

Explanation

Carbon monoxide binds hemoglobin with an affinity far greater than oxygen, reducing oxygen-carrying capacity and shifting the oxyhemoglobin dissociation curve to the left. This impairs both delivery and release of oxygen to tissues.

Question 19Scientific and Clinical Foundations of Toxicology

A substance is classified as a known human carcinogen by an authoritative agency. Which of the following best describes the regulatory implication of that classification?

  1. The classification guarantees that the substance is carcinogenic in all animal species
  2. The substance is treated as a carcinogenic hazard, and exposure should be minimized through risk management Correct answer.
  3. The substance causes cancer only through genotoxic mechanisms
  4. The substance is safe below a specific numeric dose that applies to all people

Explanation

Hazard classification identifies a substance's intrinsic carcinogenic potential and drives risk management to reduce exposure. It does not establish a universally safe dose or specify the mechanism of action.

Question 20Scientific and Clinical Foundations of Toxicology

Which of the following best explains the role of uncertainty factors in deriving a reference dose from a NOAEL?

  1. They account for interspecies differences, human variability, and database limitations Correct answer.
  2. They increase the NOAEL to reflect anticipated human exposure
  3. They eliminate the need for toxicological studies
  4. They convert a NOAEL into an LD50

Explanation

Uncertainty factors are applied to the NOAEL to account for animal-to-human extrapolation, variation among humans, and gaps such as subchronic-to-chronic extrapolation. The result is a reference dose intended to be protective of sensitive populations.

Question 21Scientific and Clinical Foundations of Toxicology

Which of the following describes the difference between hazard identification and risk characterization in risk assessment?

  1. Hazard identification applies uncertainty factors, whereas risk characterization performs animal testing
  2. Hazard identification estimates exposure, whereas risk characterization determines intrinsic toxicity
  3. Hazard identification and risk characterization are interchangeable terms
  4. Hazard identification determines whether an agent can cause harm, whereas risk characterization integrates hazard, dose-response, and exposure to estimate risk Correct answer.

Explanation

Hazard identification asks whether an agent has the potential to cause adverse effects. Risk characterization combines that information with dose-response and exposure assessment to describe the likelihood and severity of harm in a population.

Question 22Scientific and Clinical Foundations of Toxicology

A chemical requires metabolic activation to exert its toxicity. Which of the following observations would most strongly support this conclusion?

  1. Toxicity occurs equally in all species regardless of metabolism
  2. Toxicity is independent of dose and route
  3. Toxicity is greater in animals with higher activity of the activating enzyme and is reduced by an enzyme inhibitor Correct answer.
  4. Toxicity is reduced when the parent compound is administered directly

Explanation

If toxicity depends on bioactivation, increasing the activating enzyme should increase injury, and inhibiting it should protect. Such modulation by enzyme activity is strong evidence that a metabolite rather than the parent compound mediates the effect.

Question 23Scientific and Clinical Foundations of Toxicology

Two chemicals produce the same endpoint, and their dose-response curves are parallel. Chemical A has an ED50 of 10 mg/kg and chemical B has an ED50 of 40 mg/kg. What is the relative potency of A compared with B?

  1. A is forty times more potent than B
  2. A is one-fourth as potent as B
  3. A and B are equipotent
  4. A is four times more potent than B Correct answer.

Explanation

Relative potency is the ratio of equieffective doses, here 40 divided by 10, which equals 4. Because A requires a lower dose to achieve the same effect, A is four times more potent than B.

Question 24Scientific and Clinical Foundations of Toxicology

A compound is a potent inhibitor of the multidrug resistance transporter P-glycoprotein. Which effect on co-administered substrate drugs is most plausible?

  1. Increased renal filtration of substrate drugs
  2. Increased intracellular and systemic exposure of substrate drugs through reduced efflux Correct answer.
  3. No effect because P-glycoprotein only transports endogenous compounds
  4. Decreased systemic exposure of substrate drugs through enhanced efflux

Explanation

P-glycoprotein is an ATP-dependent efflux pump that limits absorption and promotes elimination of many drugs. Inhibiting it reduces efflux, which can raise intracellular concentrations and systemic exposure of substrates.

Question 25Scientific and Clinical Foundations of Toxicology

Which of the following best explains why a non-genotoxic carcinogen may be regulated using a threshold approach, whereas a genotoxic carcinogen is often assumed to have no threshold?

  1. Genotoxic carcinogens are always more potent than non-genotoxic carcinogens
  2. Threshold approaches apply only to carcinogens that act on hormone receptors
  3. Genotoxic carcinogens can produce DNA damage at any dose, whereas non-genotoxic carcinogens typically act through mechanisms requiring sustained cellular perturbation Correct answer.
  4. Non-genotoxic carcinogens do not cause cancer in animals

Explanation

Direct DNA-reactive agents can, in principle, produce a mutagenic hit at any exposure level, supporting a non-threshold default. Non-genotoxic carcinogens act through processes such as cytotoxicity, proliferation, or hormonal perturbation, which generally require a sufficient dose to disrupt homeostasis.

Question 26Scientific and Clinical Foundations of Toxicology

Which of the following best describes the primary mechanism by which arsenic exerts its acute toxic effects at the cellular level?

  1. Inhibition of pyruvate dehydrogenase by binding to lipoic acid
  2. Disruption of oxidative phosphorylation by inhibiting cytochrome c oxidase
  3. Binding to sulfhydryl groups on enzymes, particularly those involved in cellular respiration Correct answer.
  4. Competitive antagonism of calcium channels in cardiac tissue

Explanation

Arsenic has a high affinity for sulfhydryl groups and binds to vicinal dithiols in enzymes such as pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, disrupting cellular respiration and causing ATP depletion. This mechanism underlies its acute toxicity and is distinct from other metals or inhibitors.

Question 27Scientific and Clinical Foundations of Toxicology

A 45-year-old man is brought to the emergency department after ingesting an unknown amount of methanol. He has visual disturbances and metabolic acidosis. Which of the following is the most appropriate initial treatment to prevent further toxicity?

  1. Hemodialysis
  2. Intravenous sodium bicarbonate
  3. Fomepizole or ethanol therapy Correct answer.
  4. Activated charcoal administration

Explanation

Methanol itself is relatively nontoxic, but it is metabolized by alcohol dehydrogenase to formaldehyde and then to formic acid, which causes metabolic acidosis and visual damage. Fomepizole or ethanol competitively inhibits alcohol dehydrogenase, preventing formation of toxic metabolites and is the first-line antidotal therapy. Sodium bicarbonate and hemodialysis are supportive measures but do not block metabolism.

Question 28Scientific and Clinical Foundations of Toxicology

In the context of toxicokinetics, which of the following best explains why a highly lipophilic compound with a large volume of distribution (Vd) may have a prolonged elimination half-life even if its clearance is high?

  1. Half-life is directly proportional to Vd and inversely proportional to clearance, so a large Vd prolongs half-life when clearance is high. Correct answer.
  2. A large Vd indicates extensive tissue binding, which reduces the free fraction available for metabolism and thus decreases clearance.
  3. High clearance always results in a short half-life regardless of Vd because clearance determines the rate of elimination.
  4. Lipophilic compounds are primarily eliminated unchanged in urine, leading to slower elimination.

Explanation

The elimination half-life is determined by the relationship t1/2 = (0.693 × Vd) / CL. Therefore, a very large Vd can prolong half-life even when clearance is high, because the drug is extensively distributed into tissues and only slowly redistributes to the eliminating organs. This principle is important in interpreting drug persistence and designing dosing regimens.

Question 29Scientific and Clinical Foundations of Toxicology

A chemical is classified as a probable human carcinogen based on animal studies. In the absence of human data, which of the following risk assessment approaches is most appropriate for deriving a cancer slope factor?

  1. Use the NOAEL from a chronic bioassay and apply a 100-fold uncertainty factor.
  2. Use a benchmark dose approach with a 10% response level and divide by a modifying factor.
  3. Apply a linearized multistage model to the animal dose-response data after allometric scaling to humans. Correct answer.
  4. Assume a threshold and use the reference dose approach with an additional 10-fold factor for carcinogenicity.

Explanation

For potential carcinogens without human data, the default approach is to use a linearized multistage model or other low-dose extrapolation from animal tumor data, after adjusting doses to human equivalents via allometric scaling. This yields a cancer slope factor (or unit risk) that is used for low-dose risk estimation. Threshold approaches are generally not used for genotoxic carcinogens.

Question 30Scientific and Clinical Foundations of Toxicology

A 3-year-old child presents with abdominal pain, anemia, and encephalopathy. Blood lead level is 85 µg/dL. Which of the following best explains the pathophysiological mechanism of lead-induced anemia?

  1. Lead induces microcytic anemia by interfering with iron absorption in the gut.
  2. Lead causes hemolysis by oxidizing hemoglobin to methemoglobin.
  3. Lead inhibits ferrochelatase and delta-aminolevulinic acid dehydratase, impairing heme synthesis. Correct answer.
  4. Lead stimulates erythropoietin production, leading to ineffective erythropoiesis.

Explanation

Lead inhibits two key enzymes in the heme biosynthetic pathway: delta-aminolevulinic acid dehydratase (ALAD) and ferrochelatase. This leads to decreased heme production and accumulation of protoporphyrin, resulting in microcytic anemia. The other options describe mechanisms not attributable to lead.

Question 31Pharmacokinetics and Toxicokinetics

In a first-order one-compartment model after a single intravenous bolus, which parameter determines the fraction of the dose eliminated per unit time?

  1. Clearance (CL)
  2. Elimination rate constant (k) Correct answer.
  3. Volume of distribution (Vd)
  4. Area under the curve (AUC)

Explanation

For first-order elimination the rate constant k describes the fractional rate of decline of drug amount, with units of reciprocal time. Volume and clearance scale concentrations and total exposure but do not themselves express the fraction removed per unit time.

Question 32Pharmacokinetics and Toxicokinetics

A drug follows linear one-compartment kinetics with a half-life of 8 hours. Approximately what fraction of the dose remains in the body 24 hours after an intravenous bolus?

  1. About 12.5% Correct answer.
  2. About 6.25%
  3. About 25%
  4. About 50%

Explanation

Twenty-four hours equals three half-lives, so the remaining fraction is 0.5 raised to the third power, or 12.5%. Each half-life halves the amount present, giving 50%, then 25%, then 12.5% at successive 8-hour intervals.

Question 33Pharmacokinetics and Toxicokinetics

Which statement correctly describes the relationship between clearance, volume of distribution, and elimination half-life in a linear one-compartment system?

  1. Half-life is independent of both clearance and volume of distribution
  2. Half-life increases when clearance increases at constant volume
  3. Half-life is proportional to volume of distribution and inversely proportional to clearance Correct answer.
  4. Half-life depends only on the dose administered

Explanation

Half-life equals 0.693 times volume of distribution divided by clearance, so larger distribution volume prolongs half-life while higher clearance shortens it. This relationship holds only under linear kinetics.

Question 34Pharmacokinetics and Toxicokinetics

Which route of administration completely avoids first-pass hepatic metabolism?

  1. Oral
  2. Intraperitoneal
  3. Rectal (upper portion)
  4. Intravenous Correct answer.

Explanation

An intravenous dose enters the systemic circulation directly, so no fraction is extracted by the liver before reaching the general circulation. Oral and upper rectal absorption deliver drug to the portal vein, subjecting it to hepatic first-pass extraction.

Question 35Pharmacokinetics and Toxicokinetics

A 70 kg patient receives a 500 mg intravenous bolus of a drug with a volume of distribution of 50 L. What is the approximate initial plasma concentration?

  1. 50 mg/L
  2. 1 mg/L
  3. 5 mg/L
  4. 10 mg/L Correct answer.

Explanation

Concentration equals dose divided by volume of distribution, so 500 mg divided by 50 L gives 10 mg/L. This calculation assumes instantaneous mixing and a one-compartment model.

Question 36Pharmacokinetics and Toxicokinetics

Which clearance organ is primarily responsible for removing a highly lipophilic, uncharged drug that is extensively metabolized?

  1. Skin
  2. Liver Correct answer.
  3. Lung
  4. Kidney

Explanation

The liver is the principal site of metabolic clearance for lipophilic drugs, converting them to more polar metabolites. Renal clearance handles mainly polar, filterable compounds rather than extensive metabolism.

Question 37Pharmacokinetics and Toxicokinetics

Which parameter best quantifies the total systemic exposure after a single dose in a linear system?

  1. Area under the concentration-time curve Correct answer.
  2. Elimination rate constant
  3. Time to peak concentration
  4. Peak plasma concentration

Explanation

AUC integrates concentration over time and is proportional to the administered dose divided by clearance. Peak concentration and time to peak reflect rate of absorption rather than total exposure.

Question 38Pharmacokinetics and Toxicokinetics

Two formulations of the same drug have identical AUC but different peak concentrations and times to peak. Which conclusion is supported?

  1. They are bioequivalent in extent but not in rate Correct answer.
  2. They are bioequivalent in both rate and extent
  3. They differ in clearance
  4. They are not bioequivalent in extent

Explanation

Bioequivalence requires similarity in both extent (AUC) and rate (Cmax and Tmax) of absorption. Equal AUC shows comparable extent, but differing Cmax and Tmax indicate different absorption rates, so rate bioequivalence is not established.

Question 39Pharmacokinetics and Toxicokinetics

A drug is 90% bound to plasma albumin. Which statement about its distribution and filtration is correct?

  1. Bound drug is the pharmacologically active fraction
  2. The entire plasma concentration is available for glomerular filtration
  3. Binding to albumin increases the drug's volume of distribution
  4. Only the unbound fraction is available for filtration and receptor binding Correct answer.

Explanation

Only free, unbound drug crosses membranes to reach receptors and is filtered at the glomerulus. Extensive protein binding restricts distribution and limits filtration, which is why the unbound fraction drives pharmacologic effect.

Question 40Pharmacokinetics and Toxicokinetics

A patient with severe renal impairment takes a drug eliminated almost entirely unchanged by the kidney. What is the most appropriate initial adjustment?

  1. Switch to a higher loading dose with the same maintenance regimen
  2. No adjustment is needed because half-life is unchanged
  3. Extend the dosing interval or reduce the dose according to reduced clearance Correct answer.
  4. Increase the dose to compensate for reduced elimination

Explanation

When renal clearance falls, total clearance falls and half-life lengthens, so maintenance dosing must be reduced or the interval extended to avoid accumulation. Loading dose is based on volume of distribution and usually remains unchanged.

Question 41Pharmacokinetics and Toxicokinetics

Which statement about zero-order elimination is accurate?

  1. Half-life is constant across all concentrations
  2. Clearance increases proportionally with concentration
  3. A constant amount of drug is eliminated per unit time regardless of concentration Correct answer.
  4. A constant fraction of the drug is eliminated per unit time

Explanation

In zero-order kinetics the eliminating enzymes are saturated, so a fixed amount is removed per unit time independent of concentration. Consequently half-life is not constant and increases as concentration rises.

Question 42Pharmacokinetics and Toxicokinetics

A drug follows Michaelis-Menten (capacity-limited) kinetics. At concentrations far below Km, elimination approximates which behavior?

  1. Zero-order elimination
  2. Elimination rate becomes independent of concentration
  3. First-order elimination Correct answer.
  4. No elimination occurs

Explanation

When concentration is much less than Km, the enzyme is far from saturation and the rate is approximately proportional to concentration, resembling first-order kinetics. Near or above Km the process shifts toward zero-order.

Question 43Pharmacokinetics and Toxicokinetics

Which change most likely increases the volume of distribution of a weakly acidic drug?

  1. Decreased lipophilicity
  2. Decreased tissue binding
  3. Increased plasma protein binding
  4. Increased tissue affinity relative to plasma Correct answer.

Explanation

Volume of distribution rises when drug partitions into tissues more than plasma, because plasma concentration falls for a given dose. Increased plasma binding and reduced lipophilicity tend to keep drug in the vascular space and lower the apparent volume.

Question 44Pharmacokinetics and Toxicokinetics

A drug has a hepatic extraction ratio of 0.9. Which statement about its oral bioavailability is most accurate?

  1. Oral bioavailability is unaffected by hepatic blood flow
  2. Oral bioavailability is high because hepatic clearance is high
  3. Oral bioavailability equals one because extraction is complete
  4. Oral bioavailability is low because extensive first-pass extraction removes most absorbed drug Correct answer.

Explanation

For a high-extraction drug, most absorbed drug is removed during its first pass through the liver, so systemic bioavailability after oral dosing is low. Such drugs also show clearance that is sensitive to changes in hepatic blood flow.

Question 45Pharmacokinetics and Toxicokinetics

Which statement best describes the significance of a drug's steady-state concentration during multiple dosing?

  1. It is reached after about four to five half-lives when dosing rate equals elimination rate Correct answer.
  2. It increases indefinitely with continued dosing
  3. It equals the peak concentration after the first dose
  4. It is reached after approximately one half-life regardless of dosing

Explanation

Steady state occurs when the rate of drug input equals the rate of elimination, typically after four to five half-lives of repeated dosing. At that point concentrations fluctuate around a stable average rather than rising indefinitely.

Question 46Pharmacokinetics and Toxicokinetics

A patient on a maintenance regimen shows rising trough concentrations over several days with no change in dose. Which explanation is most consistent?

  1. The drug has become more rapidly absorbed
  2. The drug follows zero-order elimination and has accumulated Correct answer.
  3. The patient's clearance has increased
  4. Plasma protein binding has decreased

Explanation

Progressive accumulation of trough concentrations despite a constant dose suggests capacity-limited, zero-order elimination in which clearance falls as concentrations rise. Increasing clearance would lower, not raise, concentrations over time.

Question 47Pharmacokinetics and Toxicokinetics

Which best explains why a loading dose is used when initiating therapy with a drug that has a long half-life?

  1. To increase the drug's clearance
  2. To shorten the drug's elimination half-life
  3. To reduce the maintenance dose required
  4. To reach therapeutic concentrations rapidly without waiting several half-lives Correct answer.

Explanation

A loading dose rapidly fills the volume of distribution to therapeutic concentrations, avoiding the delay of four to five half-lives otherwise needed to reach steady state. It does not alter the maintenance dose, half-life, or clearance.

Question 48Pharmacokinetics and Toxicokinetics

Which statement correctly describes enterohepatic recirculation?

  1. It prolongs exposure because drug reabsorbed from the gut re-enters the systemic circulation Correct answer.
  2. It occurs only after intravenous administration
  3. It eliminates drug exclusively in feces without reabsorption
  4. It shortens the apparent half-life by increasing biliary excretion

Explanation

Drug excreted in bile can be deconjugated by gut flora and reabsorbed, creating a secondary absorption phase and prolonging apparent half-life. This recycling can produce multiple peaks in the concentration-time profile.

Question 49Pharmacokinetics and Toxicokinetics

A drug is eliminated by both hepatic metabolism and renal excretion. Total clearance is best estimated as which of the following?

  1. The difference between hepatic and renal clearance
  2. The sum of hepatic and renal clearance Correct answer.
  3. The product of hepatic and renal clearance
  4. The larger of the two clearance values alone

Explanation

Clearance from parallel elimination pathways is additive, so total clearance equals the sum of individual organ clearances. This assumes the pathways act independently and do not interact.

Question 50Pharmacokinetics and Toxicokinetics

A drug's renal clearance exceeds the glomerular filtration rate but is less than renal plasma flow. Which process best explains this finding?

  1. Complete absence of protein binding
  2. Net tubular secretion Correct answer.
  3. Glomerular filtration alone
  4. Extensive tubular reabsorption

Explanation

Renal clearance greater than filtration rate indicates that tubular secretion adds drug to the tubular fluid beyond what is filtered. Clearance below renal plasma flow shows secretion is not maximal and reabsorption may partially offset it.